Introduction
Duck plague (DP), also known as duck viral enteritis (DVE), is an acute, febrile, and septicemic infectious disease caused by the duck plague virus (DPV), also identified as Anatid herpesvirus 1 (AnHV-1). This highly pathogenic and rapidly spreading virus infects ducks, geese, and other Anseriformes (Dhama et al., 2017; Kaleta, et al., 2007). DPV exhibits high susceptibility across all age groups of waterfowl, often resulting in extremely high morbidity and mortality rates—up to 100%.
The principal clinicopathological manifestations following infection include widespread hemorrhaging in the digestive tract, visceral organs, and intestinal mucosa, focal necrosis in parenchymatous organs, and severe lesions in lymphoid tissues (Chang, et al., 2011; Qi, et al., 2009). The disease was first confirmed and documented in China in 1959 by Professor Huang Yinxian of the former South China Agricultural College (Wang, et al., 2013). Since then, DP has become one of the most significant diseases threatening the waterfowl industry in China, causing persistent and severe economic losses.
Although vaccines are currently available for the prevention and control of DP, their immune-protective efficacy remains limited and has not succeeded in fully interrupting viral transmission and epidemic spread (Liu, et al., 2011). What is even more challenging is that there is still a lack of effective drugs specifically capable of treating DPV infection in clinical practice. Therefore, the development of new and efficient anti-DPV drugs has become a key scientific issue that needs to be urgently addressed at present.
DPV, an α-herpesvirus of the genus Mardivirus, has viral particles structured with a core, capsid, tegument, and envelope—with the core and capsid forming the nucleocapsid, and tegument proteins linking the capsid to the envelope (the outermost layer, composed of glycoproteins) (Guiping, et al., 2007). Its particle assembly and egress in host cells follow a primary envelopment–de-envelopment–secondary envelopment process (Kelly, et al., 2009; Lee, et al., 2008). The conserved herpesvirus tegument protein UL51 participates in primary/secondary envelopment, particle assembly/release, and cell-to-cell spread.
HSV-1 UL51 deletion does not affect nucleocapsid formation but impairs perinuclear export and reduces cytoplasmic enveloped mature particles (Nozawa, et al., 2005). Localized to the Golgi apparatus (Nozawa, et al., 2003), UL51 deletion in BHV-1 causes nucleocapsid accumulation, incomplete secondary envelopment, and severe growth defects (Raza et al., 2016). Mature DPV particles are transported via Golgi-derived vesicles to the plasma membrane and released by exocytosis.
Herpesvirus envelope glycoproteins (e.g., gB, gC, gD, gE, gG, gH) mediate viral recognition, attachment, and host cell invasion (Fuchs, et al., 2012). DPV gC, encoded by UL44, is key for attachment, release, stability, and virulence—its homologs in HSV-1, PRV, and BHV-1 bind cell surface HSPGs via HBDs to facilitate virus–cell attachment (Nauwynck, 1997) (Tal-Singer, et al., 1995). Glycoproteins can also synergize to modulate virulence: PRV mutants lacking both gC and gD show drastically reduced infectivity (Karger, et al., 1998).
Brefeldin A (BFA) is a macrocyclic lactone antibiotic isolated from the fungus Penicillium brefeldianum. BFA has been widely used to analyze membrane trafficking mechanisms. It primarily acts by inhibiting protein transport from the endoplasmic reticulum (ER) to the Golgi apparatus, inducing the disassembly of the Golgi structure and causing its cisternae to redistribute reversibly into the ER, thereby blocking conventional protein secretion (Fujiwara, et al., 1988; Klausner, et al., 1992).
At the molecular level, BFA inhibits the guanine nucleotide exchange factor (GEF) of ADP-ribosylation factor 1 (ARF1) and suppresses the GTPase activity of ARF1 (Donaldson, et al., 1992), which primarily regulates the formation of coatomer protein I (COPⅠ)-coated vesicles during vesicular transport by recruiting coat proteins for trafficking between the ER and Golgi apparatus (Zeghouf, et al., 2005). The biosynthesis of viral glycoproteins in enveloped viruses relies on the ER-to-Golgi transport pathway. It has been reported that BFA inhibits the formation of enveloped viruses such as coronaviruses (CoV) and Ebola virus (EBOV), a mechanism attributed to the disruption of ER-to-Golgi transport of viral glycoproteins (Tamura, et al., 1968; Yamayoshi, et al., 2010).
Similarly, BFA significantly inhibits viral particle assembly by suppressing the accumulation of the SARS-CoV-2 M protein in the ER–Golgi intermediate compartment (ERGIC), where the M protein functions as a central regulator of coronavirus assembly and depends on ARF1 for proper subcellular localization. (Zhang, et al., 2025). During HSV-1 infection, BFA blocks STING trafficking from the Golgi into CD63-positive exosomes to export the cell (Dogrammatzis, et al., 2024).
These findings suggest that BFA not only affects the viral life cycle but may also modulate host antiviral immune signaling pathways. However, the potential inhibitory effect of BFA on DPV infection and its mechanism, particularly concerning virion envelopment, remain to be elucidated.
In this study, we first evaluated the impact of BFA at different concentrations on DPV infection, and then systematically explored the effect of BFA treatment on the life cycle of DPV. On this basis, further analyze whether BFA affects the localization and distribution of DPV envelope proteins, as well as the assembly process of DPV viral particles, thereby causing an inhibitory effect on DPV infection. The results show that BFA can effectively inhibit the replication of DPV and its spread between cells.
From a mechanistic perspective, BFA can affect the distribution of DPV envelope proteins. In the case of DPV infection, BFA can inhibit the release of nucleocapsid and the encapsulation of viral particles, thereby blocking the maturation of viral particles. In conclusion, this study reveals that BFA, as a promising antiviral drug, can effectively inhibit DPV infection.
Materials and methods
Ethics statement
All animal experiments were conducted in accordance with the national standard guidelines. The duck embryos used in the experiment were purchased from duck farms that had not been vaccinated with the DPV vaccine. This study complies with the experimental operation procedures of Sichuan Agricultural University and the approval of the Animal Welfare Committee (approved permit number SYXK 2019-187).
Cells and viruses
Duck embryo fibroblasts (DEF) cells were derived from 9-day-old duck embryos and cultured in Dulbecco's modified Eagle's Medium (DMEM; Gibco Life Technologies, Shanghai, China), 10% fetal bovine serum (FBS; YEASEN, Shanghai, China) and 1% penicillin-streptomycin. Primary cells were cultured for 24 hours and then subcultured for subsequent experiments. All cells were cultured in an incubator with 37°C and 5% CO2.
The CHv strain used in this study is a highly toxic DPV strain isolated and identified in our research center. Based on it, a DPV recombinant strain expressing green fluorescent protein (DPV-CHv-GFP) was constructed.
Reagents and plasmids
Brefeldin A (BFA) was purchased from MedChemExpress and diluted with dimethyl sulfoxide (DMSO), with a purity of 99.82%. The anti-Flag (M185-3) and anti-HA (M180-3) antibodies were from MBL, and the Alexa FluorTM 488 conjugated goat anti-mouse IgG (H + L) fluorescent secondary antibody was purchased from ThermoFisher.
The eukaryotic expression plasmids pCAGGS-UL51-Flag and pCAGGS-UL44-HA were preserved by the Poultry Disease Control Research Center of Sichuan Agricultural University. Plasmids were transfected into DEF cells using Hieff TransTM liposomal transfection reagent (40802ES02) from Yeasen Biotech.
Viral infection and determination of tissue culture infectious dose 50 (TCID50)
For viral infections, the virus was diluted with DMEM medium. The infected cells were incubated at 37°C for 1 h. Then, the cells were washed 3 times with PBS to remove the residual viral solution and continued to be cultured with DMEM containing 2% FBS and 1% penicillin-streptomycin.
The cell supernatant was collected and the tissue culture infectious dose 50 (TCID50) of DPV-CHv-GFP was determined by the method described before (Zhou, et al., 2016).
Analysis of viral genome copy number
Total viral DNA was isolated from infected cells using the Magen HiPure Viral DNA Kit (Magen, Guangzhou, China). Viral genome copy numbers were quantified by absolute quantitative PCR (q-PCR) with Premix Ex Taq (Probe qPCR) (Takara, Dalian, China). The quantitative primers were designed for the DPV UL30 gene and were previously established by our laboratory(Tian, et al., 2021): DPV UL30-F: TTTCCTCCTCCTCGCTGAGTG, DPV UL30-R: CCAGAAACATACTGTGAGAGT.
A standard curve was generated using serially diluted plasmids containing the full-length UL30 coding sequence, which were amplified under the same qPCR conditions as the experimental samples. The copy number of DPV in infected cells was determined based on the standard curve and normalized to 1 µg of total DNA.
Analysis of antiviral activity
DEF were infected with DPV-CHv-GFP at 37°C for 1 h. The cells were washed with PBS 3 times and then replaced with fresh DMEM medium containing different concentrations of BFA or DMSO for 24 h. The cell supernatant was collected to determine TCID50, and the fluorescent plaques of DPV-CHv-GFP were observed by fluorescence microscope.
Cytotoxicity test
DEF cells were treated with BFA of different concentrations for 36 h, and the cell viability was determined using the cell counting CCK-8 kit (TargetMOI, c0005) according to the manufacturer's instructions.
Analysis of time-addition and antiviral duration
In the antiviral time-addition experiment, DEF cells were infected with DPV-CHv-GFP at a dose of 1 MOI for 1 h. BFA was added at three time points: before infection (2 h before viral incubation), inter infection (mid-stage of viral incubation), and after infection, respectively. To eliminate the residual interference of BFA in the determination of virus titration, the collected cell culture supernatant was incubated with DEF cells for 2 h, and then the cells were washed with PBS and fresh culture medium was replaced.
36 h after infection, the supernatant was collected for the determination of TCID50, and at the same time, the infected cells were collected for the detection of genomic DPV DNA levels by qPCR. To further analyze the antiviral duration, DEF cells were infected with DPV-CHV-GFP of 1 MOI for 1 h, and then 0.05 µg/mL BFA was added. The supernatants were collected at 24, 48, 72 and 96 h for TCID50 determination, and the infected cells were collected to detect the genomic DPV DNA level.
Analysis of virus adsorption, endocytosis, replication, release, and intercellular transmission
To explore the impact of BFA on the life cycle of DPV, the virus infection stages were evaluated based on the life cycle of herpesviruses. In the virus adsorption phase, DEF cells were precooled at 4°C for 1 h and then incubated with 0.001 MOI of DPV-CHV-GFP and BFA (0.05 µg/mL) or DMSO for 2 h at 4°C. After the adsorption, the cells were washed 3 times with precooled PBS, covered with DMEM medium containing 1% methylcellulose and 2% FBS, and cultured at 37°C for 72 h.
The number of viral plaques was directly counted by calculating the average value of repeated Wells.
In the virus endocytosis phase, DEF cells were precooled at 4°C for 1 h and then incubated with DPV-CHv-GFP of 0.001 MOI at 4°C for 2 h. The cells were washed 3 times with precooled PBS, then replaced with fresh DMEM medium containing BFA (0.05 µg/mL) or DMSO, and cultured at 37°C for 3 h. After gentle washing with PBS, DMEM containing 1% methylcellulose and 2% FBS was covered and incubated at 37°C for 72 h.
Finally, the average number of plaques in each repeate well was counted.
In the viral genome replication stage, DEF cells were incubated with DPV-CHv-GFP of 0.1 MOI at 37°C for 6 h, washed in PBS for 3 times, and then replaced with fresh DMEM medium containing BFA (0.05 µg/mL) or DMSO. Cells were collected at 7, 8, 9 and 10 h after infection and DNA was extracted. The copy number of DPV genome was determined by absolute quantitative PCR.
In the virus particle release stage, DEF cells were infected with 1 MOI DPV-CHv-GFP at 37°C for 18 h. After being washed with PBS 3 times, fresh DMEM medium containing BFA (0.05 µg/mL) or DMSO was replaced for continued culture. The supernatant was collected at 15, 30, 45 and 60 min after drug addition to detect the virus TCID50.
For the intercellular transmission ability of virus, DEF cells were incubated with 0.001 MOI of DCV-CHV-GFP at 37°C for 1 h, washed 3 times with PBS and covered with 1% methylcellulose and BFA (0.05 µg/mL) or DMSO for 36 h. Fluorescent plaques were observed under a fluorescence microscope. Ten fluorescent plaques were randomly selected from each group, and their areas were measured and compared with the DMSO treatment group (set to 100%) for statistical analysis.
Immunofluorescence assay (IFA) and confocal microscopy
DEF cells were seeded on cover slips of 12-well plates. When the cells reached 80% confluence, they were transfected with the specified plasmid. After 30 h, BFA (0.05 µg/mL) or DMSO was added and treated for 6 h.
The cells were washed with PBS for 3 times, fixed with 4% paraformaldehyde for 20 min, washed with PBST (LABLEAD, L1329) for 3 times, and then permeated with 0.25% Triton X-100 for 10 min. After washing with PBST 3 times, seal with 10% sheep serum (BOSTER, AR1009) at room temperature for 45 min. PBST was washed 3 times and then incubated with the corresponding primary antibody at 37°C for 1.5 h.
After PBST washing 3 times, the fluorescent secondary antibody was bound under dark conditions and incubated at room temperature for 45 min. Finally, 4 ', 6-diamino-2-phenylindole (DAPI; Solarbio, C0065) staining for 5 min. The fluorescence signal was observed using an OLYMPUS FV4000 confocal microscope.
Transmission electron microscopy
DEF cells were infected with DPV-CHv-GFP at 5 MOI for 2 h, washed three times with PBS and cultured at 37°C for 12 h, followed by treatment with 0.05 µg/mL Brefeldin A for 6 h, and DMSO was used as the control. Cell samples were collected, centrifuged at 3000 r/min for 15 min at room temperature, and then fixed in 2.5% glutaraldehyde. After fixation, they were sent to Chengdu Lilai Biotechnology for electron microscope preparation and photography.
Statistical analysis
The data were presented in the form of SD or SEM, and all experiments were repeated 3 times. Graphs were plotted using GraphPad Prism software, and the data were analyzed using Student 's t-test. Statistical significance levels were marked with asterisks (* P < 0.05;** p < 0.01;*** p < 0.001;**** p < 0.0001).
Results
Brefeldin A inhibits DPV infection in DEF cells
Studies have shown that BFA can inhibit the infection of herpes simplex virus (HSV) (Tebaldi, et al., 2020), but the specific antiviral mechanism has not been analyzed. Both DPV and HSV-1 belong to the alpha herpesvirus. To explore whether BFA has an anti-infective effect on duck herpesvirus DPV, we tested it on DEF cells.
DEF cells were infected with 1 MOI of DPV-CHv-GFP for 1 h, and then 0.01, 0.02, 0.05, 0.1 and 0.2 µg/mL of BFA were added and DMSO was used as a control. The results showed that the BFA concentration of 0.05 µg/mL significantly inhibited the viral fluorescent spots, and 0.1 and 0.2 µg/mL treatments could only detect a small number of fluorescent spots (Fig. 1A).
At the same time, the cells and supernatant of the control group and the BFA treatment group were collected to detect the gene copy number and virus titer (TCID50) of DPV. With the increase of BFA concentration, the replication ability and virus titer level of DPV gradually decreased (Fig. 1B and C).
Meanwhile, the effect of BFA on the viability of DEF cells was detected by the CCK-8 method. The results showed that neither low nor high concentrations of BFA had an impact on the viability of DEF cells (Fig. 1D).
In view of this, 0.05 µg/mL was selected for the following study. These data suggest that BFA has an anti-DPV effect in DEF cells.Fig. 1Brefeldin A inhibits DPV infection in DEF cells.
(A-C) DEF cells were infected with DPV-CHv-GFP at 1 MOI for 1 h, then treated with different concentrations of Brefeldin A, DMSO was added as control. The viral fluorescence spots were photographed under fluorescence microscope at 24 hours post infection (hpi). The scale bar is 100 µm (A).
The infected cells were collected and the copy number of the DPV gene was detected by Q-PCR (B), and the cell supernatant was collected to determine the virus titer TCID50 (C). (D) DEF cells were treated with different concentrations of Brefeldin A for 48 h, and then the cell viability was determined using the CCK-8 cell viability assay kit.Fig. 1 dummy alt text
Brefeldin A therapeutically inhibits DPV infection
Next, we explored whether BFA achieved its antiviral effect by preventing virus infection or inhibiting virus growth. Based on the above results, 0.05 µg/mL was selected as the main working concentration. BFA was added before, during and after DPV virus infection.
The results showed that the viral fluorescent spots were significantly inhibited only when BFA was added after virus infection (Fig. 2A), and the viral copy number and viral titer also showed the same results (Fig. 2B and C).
These data indicate that BFA can therapeutically inhibit DPV infection in DEF cells.Fig. 2Brefeldin A therapeutically inhibits DPV infection. (A-C) DEF cells were infected with DPV-CHv-GFP at 1 MOI, and 0.05 µg/mL Brefeldin A was added before, in-the-meanwhile (inter), and after infection, DMSO was added as control.
The viral fluorescence spots were photographed under fluorescence microscope at 24 hpi. The scale bar is 100 µm (A). The infected cells were collected and the copy number of the DPV gene was detected by Q-PCR (B), and the cell supernatant was collected to determine the virus titer TCID50 (C).Fig.
2 dummy alt text
Brefeldin A inhibits DPV infection within 48 h
To further explore the antiviral ability of BFA in DEF cells, we examined the duration of BFA's inhibition of viral infection. DEF cells were infected with 1 MOI of DPV-CHv-GFP and then treated with BFA. The fluorescent spots were observed at 24, 48, 72, and 96 h respectively (Fig.
3A), and the cells and supernatants were collected to detect the viral gene copy number (Fig. 3B) and viral titer (Fig. 3C).
The inhibitory effect of BFA on the fluorescent spots of DPV is the strongest at 24 and 48 h, and there is no significant inhibitory effect after 72 h. Meanwhile, the DPV gene copy number and TCID50 growth curve of the control group and the BFA treatment group were also significantly different at 24 and 48 h, indicating that BFA could inhibit DPV replication within 48 h. The above results indicate that BFA has the strongest antiviral ability at 24 and 48 h.Fig.
3Brefeldin A inhibits DPV infection within 48h. (A-C) DEF cells were infected with DPV-CHv-GFP at 1 MOI for 1 h, then treated with 0.05 µg/mL Brefeldin A, DMSO was added as control. The viral fluorescence spots were photographed under fluorescence microscope at the indicated time points of 24, 48, 72, and 96 h.
The scale bar is 100 µm (A). The infected cells were collected and the copy number of the DPV gene was detected by Q-PCR (B), and the cell supernatant was collected to determine the virus titer TCID50 (C).Fig. 3 dummy alt text
Brefeldin A affects cell-to-cell spread of the DPV
The life cycle of herpesvirus includes four stages: adsorption, endocytosis, replication and release (Atanasiu, et al., 2013). Therefore, we explored the influence of BFA on the life cycle of DPV. For the viral adsorption and endocytosis stages, no significant difference was observed in the number of viral plaques between the DMSO group and the BFA treatment group (Fig.
4A and B). For the viral replication stage, the copy number of the viral UL30 gene was detected by q-PCR, and no significant differences between groups were observed (Fig. 4C).
For the viral release stage, DEF cells were infected with 1 MOI of DPV-CHv-GFP and the cell supernatant was collected for TCID50 assay at 18 h after infection. The results showed that the BFA treatment group did not show significant inhibition compared with the control group (Fig. 4D).
The above results indicate that BFA does not directly interfere with the major stages of the DPV life cycle.Fig. 4The influence of Brefeldin A on the life cycle of DPV. (A-D) Brefeldin A was added at different stages of the viral life cycle, adsorption (A), endocytosis (B), replication (C), and release (D).
For details, please refer to the materials and methods.Fig. 4 dummy alt text
Mature herpesvirus particles can either reinfect new cells after exocytosis, or spread directly between cells. The above research results indicate that BFA has little impact on the former mode of transmission. Therefore, we further explore the influence of BFA on the intercellular transmission of DPV.
DEF cells were infected with 0.001 MOI of DPV-CHv-GFP for 1 h, and then 0.05 and 0.1 µg/mL of BFA were added. After 36 h, the viral fluorescent spots were observed. Compared with the control group, the viral fluorescent spots were significantly smaller after BFA treatment (Fig.
5A). At the same time, the viral plaques of all groups were randomly selected for statistical analysis of the area size, and the DMSO group was taken 100%, and the viral plaque area was also observed to decrease after BFA treatment (Fig. 5B).
These results suggest that BFA inhibits cell-to-cell spread of DPV.Fig. 5Brefeldin A affects cell-to-cell spread of the DPV. (A and B) DEF cells were infected with DPV-CHv-GFP at 0.001 MOI for 1 h, then treated with 0.05 µg/mL or 0.1 µg/mL of Brefeldin A, DMSO was added as control.
The viral fluorescence spots were photographed under fluorescence microscope at 36 hpi. The scale bar is 100 µm (A). The area of 10 virus fluorescent plaques in each group was randomly selected for statistical analysis, DMSO treatment group was set to 100%.
(B).Fig. 5 dummy alt text
Brefeldin A affects the distribution of DPV envelope proteins
Studies have proved that BFA can inhibit the protein transport from the endoplasmic reticulum to the Golgi apparatus and vesicle transport(Fujiwara, Oda, Yokota, Takatsuki and Ikehara, 1988). Therefore, next we explore whether BFA affects the distribution of viral envelope proteins. DEF cells were transfected with UL51-Flag (encoding cortical protein pUL51) and UL44-HA (encoding envelope glycoprotein gC) expression plasmids of DPV, and then treated with 0.05 µg/mL BFA.
The confocal results showed that UL51 and UL44 were mainly localized in the cytoplasm and were highly aggregated in the organelle region. After BFA treatment, the distribution of UL51 became more diffuse or sparsely punctate, with small dot-like structures mainly observed in the perinuclear area (Fig. 6A).
Similarly, UL44 exhibited a dispersed cytoplasmic localization after BFA treatment (Fig. 6B). Collectively, these results indicate that BFA disrupts the normal distribution patterns of both UL51 and UL44 proteins.Fig.
6Brefeldin A affects the distribution of DPV envelope proteins. (A and B) DEF cells were transfected with UL51-Flag or UL44-HA expression plasmid, and 0.05 µg/mL Brefeldin A was added 30 h after transfection, DMSO was added as control. Indirect immunofluorescence (IFA) analysis was performed 6 h after drug treatment, and the fluorescence signal was observed by confocal immunofluorescence microscope.
The scale size is 10 µm.Fig. 6 dummy alt text
Brefeldin A affects the release of nucleocapsids and virion envelopment
After entering the cell, the DNA of the DPV virus forms a capsid in the cell nucleus and undergoes primary and secondary capsule coating at the nuclear space and Golgi-derived vesicle respectively, thereby forming complete viral particles (Bigalke and Heldwein, 2016). Given our previous findings that BFA disrupts the normal distribution of DPV envelope proteins, we further investigated the effect of BFA on the envelopment process during DPV replication. DEF cells were infected with DPV-CHv-GFP at 5 MOI for 2 h, incubated at 37 °C for 12 h, and then treated with 0.05 µg/mL BFA for an additional 6 h.
DMSO was used as the control group. As shown in Fig. 7, in the mock group, cells exhibited normal morphology with no viral particles and intact organelles such as mitochondria.
In the DMSO control group, numerous immature virions enveloped by Golgi-derived vesicles were observed in the cytoplasm, along with mature viral particles near release sites (indicated by blue arrows). In contrast, BFA-treated cells exhibited pronounced accumulation of nucleocapsids in the nucleus and multiple virions lacking primary envelopes at the nuclear membrane. Only a small number of non-enveloped viral particles were detected in the perinuclear region of the cytoplasm, with no significant presence of enveloped virions (red arrows).
These results indicate that BFA inhibits the release of nucleocapsids and impairs virion envelopment during DPV infection.Fig. 7Brefeldin A affects the release of nucleocapsids and virion envelopment. (A) DEF cells were infected with DPV-CHv-GFP at 5 MOI for 2 h, cultured at 37°C for 12 h, and then treated with 0.05 µg/mL Brefeldin A for 6 h, DMSO was added as control.
Cell samples were collected, centrifuged at 3000 r/min for 15 min at room temperature, and then fixed in 2.5% glutaraldehyde. After fixation, they were sent to Chengdu Lilai Biotechnology for electron microscope preparation and photography. The blue arrows indicate Golgi vesicle encapsulated virions and mature virions, and the red arrows indicate viral nucleocapsids and immature virions.Fig.
7 dummy alt text
Discussion
Duck plague virus, as a pathogen that seriously endangers waterfowl farming, its high pathogenicity and rapid transmission ability make the development of effective antiviral strategies an urgent matter (Dhama, Kumar, Saminathan, Tiwari, Karthik, Kumar, Palanivelu, Shabbir, Malik and Singh, 2017). It is of great significance to explore compounds with broad-spectrum antiviral potential, especially drugs that can interfere with the replication and transmission ability of viruses. In this study, we systematically evaluated the inhibitory effect of BFA on DPV infection for the first time.
Our results demonstrate that BFA significantly suppresses DPV infection in DEF cells in a concentration-dependent manner, without causing obvious cytotoxicity within the tested concentration range. The antiviral activity of BFA was sustained for up to 48 h and exhibited therapeutic characteristics. Furthermore, we revealed that BFA inhibits viral infection by disrupting cell-to-cell spread rather than directly affecting the viral life cycle.
Further investigation indicated that BFA induces mislocalization of viral envelope proteins and blocks the maturation of viral particles by interfering with nuclear egress of nucleocapsids and secondary envelopment, thereby suppressing the cell-to-cell transmission capacity of the virus.
Brefeldin A (BFA) is a macrolide antibiotic. Studies have shown that it is a non-competitive inhibitor of ARF1 activation. ARF1 controls the formation of COPI-coated vesicles, and its inactivation disrupts protein transport from the endoplasmic reticulum (ER) to the Golgi apparatus (Zeghouf, Guibert, Zeeh and Cherfils, 2005).
Given the significance of ARF1 in vesicle formation and membrane exchange processes, BFA, as its inhibitor, exhibits potent antiviral activity against enveloped viruses. This effect is attributed to BFA's inhibition of ARF1 GEF activity, which blocks the formation of COPI-coated vesicles and consequently disrupts the transport and assembly of viral proteins along the ER-to-Golgi pathway (Yamayoshi, Neumann and Kawaoka, 2010). In the present study, we found that BFA suppresses DPV infection in DEF cells in a concentration-dependent manner.
The antiviral activity was primarily exerted after viral infection rather than during viral adsorption or endocytosis, consistent with previous findings for HSV-1, in which BFA interferes with intracellular trafficking after viral entry (Tebaldi, Pritchard and Nicola, 2020). Further analysis revealed that the inhibitory effect of BFA was most significant within 48 hours after infection, indicating that its activity is time-dependent. BFA inhibits ER transport to the Golgi, leading to Golgi disaggregation and concomitantly reversibly redistributing Golgi pools to the ER.
The loss of BFA inhibitory activity after 72 hours may be due to the degradation of BFA in the culture medium, allowing the Golgi apparatus function and vesicle transport to recover.
Viral dissemination to uninfected cells occurs primarily through two distinct mechanisms: one involves transmission via the extracellular environment, and the other occurs through direct cell-to-cell contact, enabling the virus to transfer between connected cells without traversing the extracellular space. Cell-to-cell spread not only promotes viral dissemination but also facilitates immune evasion by allowing the virus to escape host immune surveillance, such as avoiding recognition by neutralizing antibodies (Jacob, et al., 2013; Sattentau, 2008). In this study, we found that BFA does not affect viral adsorption, endocytosis, genome replication, or release; however, it significantly inhibits the cell-to-cell spread of DPV, as evidenced by a marked reduction in viral plaque size.
This distinction likely reflects different temporal and mechanistic dependencies: while the release assay captured the secretion of pre-formed particles shortly after treatment, cell-to-cell spread is a continuous process that relies on the ongoing, Golgi-dependent delivery of viral components to intercellular junctions. Thus, BFA appears to selectively disrupt the vesicular trafficking required for direct viral dissemination between cells, without immediately affecting the export of already assembled virions.
Herpesvirus infection initiates when viral envelope glycoproteins bind to host cell receptors, leading to envelope fusion and cytoplasmic delivery of the viral genome. The genome is encapsidated to form nucleocapsids, which mature through sequential primary envelopment, de‑envelopment, and secondary envelopment. Progeny virions are then released and spread to neighboring cells via exocytosis or direct cell‑cell fusion.
(Heming, et al., 2017). The maturation of herpesviruses depends on the correct trafficking and localization of viral envelope proteins through the ER–Golgi network (Bigalke and Heldwein, 2016). Our results demonstrate that BFA treatment markedly alters the subcellular distribution of the DPV tegument protein UL51 and the envelope glycoprotein gC (encoded by UL44) in the cytoplasm, shifting from a concentrated pattern to a diffuse localization.
The distribution disorder of these proteins caused by BFA is very likely to disrupt the spatial coordination required for viral assembly, thereby affecting viral maturation. Transmission electron microscopy revealed abundant accumulation of nucleocapsids within the nucleus of BFA-treated cells, along with the presence of primary unenveloped virions at the nuclear membrane and a significant reduction in the number of mature virions in the cytoplasm. These observations suggest that BFA may disrupt the nuclear egress of nucleocapsids or the secondary envelopment process, thereby blocking final virion maturation.
This mechanism is consistent with findings in BHV-1 and HSV-1, where loss or impairment of UL51 function leads to perinuclear accumulation of virions and defective secondary envelopment (Nozawa, Kawaguchi, Tanaka, Kato, Kato, Kimura and Nishiyama, 2005; Raza, et al., 2016). This blockade at the primary envelopment stage is notable because BFA primarily disrupts the Golgi apparatus, which is involved in secondary envelopment in the cytoplasm. This finding raises the possibility that DPV primary envelopment may depend, directly or indirectly, on Golgi-derived components or ARF1-regulated membrane trafficking.
Another possibility is that the stagnation of the secondary envelope process prevents the primary envelope virus particles from being utilized subsequently, resulting in a backlog around the nucleus. Studies have shown that BFA can also induce alternative autophagy, which relies on a RAB9A-mediated vesicular trafficking pathway and participates in the clearance of damaged mitochondria (Zhou, et al., 2019). Given that the perinuclear region is often a site for the accumulation of autolysosomes (Liu, et al., 2023), and we found that UL51 and gC localize as faint, sparse puncta in this same region.
This observation prompts the hypothesis that BFA-induced perinuclear clustering of viral particles and envelope proteins could trigger an autolysosome-dependent degradation pathway as an antiviral host response. The specific mechanism remains to be clarified in the future. Additionally, DPV causes systemic infection in vivo, involving more complex virus–host interactions in replication, dissemination, and immune modulation.
Therefore, future studies should aim to evaluate the pharmacokinetics, tissue distribution, toxicity, and therapeutic efficacy of BFA or its derivatives in duck or other susceptible avian models. Such investigations will provide crucial evidence for the translational potential of our findings.
In summary, BFA disrupts the intracellular localization of DPV envelope proteins, thereby inhibiting the nuclear egress and secondary envelopment of nucleocapsids, and ultimately blocking virion maturation and cell-to-cell spread. This mechanism of action not only deepens our understanding of BFA's antiviral activity but also provides a theoretical foundation and potential targets for developing novel therapeutic strategies against DPV and other herpesviruses.
CRediT authorship contribution statement
Xuetong Wang: Writing – original draft, Data curation. Bin Tian: Writing – original draft, Data curation. Zaihui Liu: Software, Methodology.
Dongjie Cai: Resources, Data curation. Yanming Tian: Software, Methodology. Mingshu Wang: Software, Conceptualization.
Ying Wu: Resources. Qiao Yang: Software. Shaqiu Zhang: Methodology.
Dekang Zhu: Writing – review & editing, Data curation. Mafeng Liu: Writing – review & editing, Resources. Xinxin Zhao: Formal analysis.
Di Sun: Resources. Juan Huang: Resources. Xumin Ou: Investigation.
Zhen Wu: Project administration. Yu He: Investigation. Renyong Jia: Validation, Formal analysis.
Shun Chen: Investigation, Data curation. Anchun Cheng: Supervision, Funding acquisition.
Disclosures
The authors have no financial conflicts of interest.